{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:49:59Z","timestamp":1773683399050,"version":"3.50.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Chem."],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Natural products that contain <jats:italic>ortho<\/jats:italic>-quinones show great potential as anticancer agents but have been largely discarded from clinical development because their redox-cycling behaviour results in general systemic toxicity. Here we report conjugation of <jats:italic>ortho<\/jats:italic>-quinones to a carrier, which simultaneously masks their underlying redox activity. <jats:italic>C<\/jats:italic>-benzylation at a quinone carbonyl forms a redox-inactive benzyl ketol. Upon a specific enzymatic trigger, an acid-promoted, self-immolative C\u2013C bond-cleaving 1,6-elimination mechanism releases the redox-active hydroquinone inside cells. By using a 5-lipoxygenase modulator, \u03b2-lapachone, we created cathepsin-B-cleavable quinone prodrugs. We applied the strategy for intracellular release of \u03b2-lapachone upon antibody-mediated delivery. Conjugation of protected \u03b2-lapachone to Gem-IgG1 antibodies, which contain the variable region of gemtuzumab, results in homogeneous, systemically non-toxic and conditionally stable CD33+-specific antibody\u2013drug conjugates with in vivo efficacy against a xenograft murine model of acute myeloid leukaemia. This protection strategy could allow the use of previously overlooked natural products as anticancer agents, thus extending the range of drugs available for next-generation targeted therapeutics.<\/jats:p>","DOI":"10.1038\/s41557-022-00964-7","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T13:04:20Z","timestamp":1656421460000},"page":"754-765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Controlled masking and targeted release of redox-cycling ortho-quinones via a C\u2013C bond-cleaving 1,6-elimination"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9125-6081","authenticated-orcid":false,"given":"Lavinia","family":"Dunsmore","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0161-412X","authenticated-orcid":false,"given":"Claudio D.","family":"Navo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-4475","authenticated-orcid":false,"given":"Julie","family":"Becher","sequence":"additional","affiliation":[]},{"given":"Enrique Gil","family":"de Montes","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Guerreiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6940-8803","authenticated-orcid":false,"given":"Emily","family":"Hoyt","sequence":"additional","affiliation":[]},{"given":"Libby","family":"Brown","sequence":"additional","affiliation":[]},{"given":"Viviane","family":"Zelenay","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-639X","authenticated-orcid":false,"given":"Sigitas","family":"Mikutis","sequence":"additional","affiliation":[]},{"given":"Jonathan","family":"Cooper","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3035-8970","authenticated-orcid":false,"given":"Isaia","family":"Barbieri","sequence":"additional","affiliation":[]},{"given":"Stefanie","family":"Lawrinowitz","sequence":"additional","affiliation":[]},{"given":"Elise","family":"Siouve","sequence":"additional","affiliation":[]},{"given":"Esther","family":"Martin","sequence":"additional","affiliation":[]},{"given":"Pedro R.","family":"Ruivo","sequence":"additional","affiliation":[]},{"given":"Tiago","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Filipa P.","family":"da Cruz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5064-4379","authenticated-orcid":false,"given":"Oliver","family":"Werz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-8022","authenticated-orcid":false,"given":"George","family":"Vassiliou","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Ravn","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0105-4337","authenticated-orcid":false,"given":"Gonzalo","family":"Jim\u00e9nez-Os\u00e9s","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6594-8917","authenticated-orcid":false,"given":"Gon\u00e7alo J. L.","family":"Bernardes","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"964_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0187925","volume":"12","author":"A Rayan","year":"2017","unstructured":"Rayan, A., Raiyn, J. & Falah, M. Nature is the best source of anticancer drugs: indexing natural products for their anticancer bioactivity. PLoS ONE 12, 1\u201312 (2017).","journal-title":"PLoS ONE"},{"key":"964_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nchem.2479","volume":"8","author":"T Rodrigues","year":"2016","unstructured":"Rodrigues, T., Reker, D., Schneider, P. & Schneider, G. Counting on natural products for drug design. Nat. Chem. 8, 531\u2013541 (2016).","journal-title":"Nat. Chem."},{"key":"964_CR3","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.3390\/ijms19113533","volume":"19","author":"A Lichota","year":"2018","unstructured":"Lichota, A. & Gwozdzinski, K. Anticancer activity of natural compounds from plant and marine environment. Int. J. Mol. Sci. 19, 3533 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"964_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1124\/pr.56.1.3","volume":"56","author":"M Rooseboom","year":"2004","unstructured":"Rooseboom, M., Commandeur, J. A. N. N. M. & Vermeulen, N. P. E. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 56, 53\u2013102 (2004).","journal-title":"Pharmacol. Rev."},{"key":"964_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C. & Corva\u00efa, N. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat. Rev. Drug Discov. 16, 315\u2013337 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"964_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1021\/np5000796","volume":"77","author":"GM Cragg","year":"2014","unstructured":"Cragg, G. M., Grothaus, P. G. & Newman, D. J. New horizons for old drugs and drug leads. J. Nat. Prod. 77, 703\u2013723 (2014).","journal-title":"J. Nat. Prod."},{"key":"964_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000443404","volume":"25","author":"GM Cragg","year":"2016","unstructured":"Cragg, G. M. & Pezzuto, J. M. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med. Princ. Pract. 25, 41\u201359 (2016).","journal-title":"Med. Princ. Pract."},{"key":"964_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2174\/1568009023333854","volume":"2","author":"AB Pardee","year":"2002","unstructured":"Pardee, A. B., Li, Y. Z. & Li, C. J. Cancer therapy with beta-lapachone. Curr. Cancer Drug Targets 2, 227\u2013242 (2002).","journal-title":"Curr. Cancer Drug Targets"},{"key":"964_CR9","first-page":"A118","volume":"15","author":"Y Lu","year":"2006","unstructured":"Lu, Y., Liu, D., Li, L. & Zhou, J.-R. Tanshinone IIA, a major component of Danshen posses potent anticancer and antiangiogenic activities. Cancer Epidemiol. Biomarkers Prev. 15, A118 (2006).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"964_CR10","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1111\/jphp.13176","volume":"71","author":"P Chonsut","year":"2019","unstructured":"Chonsut, P. et al. Ethoxy mansonone G as an anticancer agent in estrogen receptor-positive and endocrine-resistant breast cancer. J. Pharm. Pharmacol. 71, 1839\u20131853 (2019).","journal-title":"J. Pharm. Pharmacol."},{"key":"964_CR11","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.bmcl.2015.01.057","volume":"25","author":"J Bian","year":"2015","unstructured":"Bian, J. et al. Synthesis and evaluation of (\u00b1)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1). Bioorg. Med. Chem. Lett. 25, 1244\u20131248 (2015).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"964_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1080\/14756366.2017.1337758","volume":"32","author":"S Burmao\u011flu","year":"2017","unstructured":"Burmao\u011flu, S. et al. Syntheses and evaluation of multicaulin and miltirone-like compounds as antituberculosis agents. J. Enzyme Inhib. Med. Chem. 32, 878\u2013884 (2017).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"964_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cclet.2010.07.009","volume":"22","author":"F Deng","year":"2011","unstructured":"Deng, F. et al. Synthesis and antitumor activity of novel salvicine analogues. Chin. Chem. Lett. 22, 25\u201328 (2011).","journal-title":"Chin. Chem. Lett."},{"key":"964_CR14","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1016\/j.bmcl.2015.04.048","volume":"25","author":"E Saruul","year":"2015","unstructured":"Saruul, E. et al. An antibacterial ortho-quinone diterpenoid and its derivatives from Caryopteris mongolica. Bioorg. Med. Chem. Lett. 25, 2555\u20132558 (2015).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"964_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jep.2008.10.004","volume":"121","author":"JR G\u00f3mez Castellanos","year":"2009","unstructured":"G\u00f3mez Castellanos, J. R., Prieto, J. M. & Heinrich, M. Red lapacho (Tabebuia impetiginosa)\u2014a global ethnopharmacological commodity? J. Ethnopharmacol. 121, 1\u201313 (2009).","journal-title":"J. Ethnopharmacol."},{"key":"964_CR16","first-page":"3706","volume":"55","author":"SM Planchon","year":"1995","unstructured":"Planchon, S. M. et al. \u03b2-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res. 55, 3706\u20133711 (1995).","journal-title":"Cancer Res."},{"key":"964_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"Y Yang","year":"2017","unstructured":"Yang, Y. et al. \u03b2-Lapachone suppresses tumour progression by inhibiting epithelial-to-mesenchymal transition in NQO1-positive breast cancers. Sci Rep. 7, 1\u201313 (2017).","journal-title":"Sci Rep."},{"key":"964_CR18","doi-asserted-by":"publisher","first-page":"11832","DOI":"10.1073\/pnas.0702176104","volume":"104","author":"EA Bey","year":"2007","unstructured":"Bey, E. A. et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by \u03b2-lapachone. Proc. Natl Acad. Sci. USA 104, 11832\u201311837 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"964_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4161\/cbt.4.1.1382","volume":"4","author":"M Ough","year":"2005","unstructured":"Ough, M. et al. Efficacy of \u03b2-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1. Cancer Biol. Ther. 4, 95\u2013102 (2005).","journal-title":"Cancer Biol. Ther."},{"key":"964_CR20","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1074\/jbc.275.8.5416","volume":"275","author":"JJ Pink","year":"2000","unstructured":"Pink, J. J. et al. NAD(P)H:quinone oxidoreductase activity is the principal determinant of \u03b2-lapachone cytotoxicity. J. Biol. Chem. 275, 5416\u20135424 (2000).","journal-title":"J. Biol. Chem."},{"key":"964_CR21","doi-asserted-by":"publisher","first-page":"7079","DOI":"10.1039\/C6SC02758J","volume":"7","author":"P Gopinath","year":"2016","unstructured":"Gopinath, P., Mahammed, A., Ohayon, S., Gross, Z. & Brik, A. Understanding and predicting the potency of ROS-based enzyme inhibitors, exemplified by naphthoquinones and ubiquitin specific protease-2. Chem. Sci. 7, 7079\u20137086 (2016).","journal-title":"Chem. Sci."},{"key":"964_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1021\/acs.chemrestox.6b00256","volume":"30","author":"JL Bolton","year":"2017","unstructured":"Bolton, J. L. & Dunlap, T. Formation and biological targets of quinones: cytotoxic versus cytoprotective effects. Chem. Res. Toxicol. 30, 13\u201337 (2017).","journal-title":"Chem. Res. Toxicol."},{"key":"964_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0891-5849(89)90162-7","volume":"6","author":"G Powis","year":"1989","unstructured":"Powis, G. Free radical formation by antitumor quinones. Free Radic. Biol. Med. 6, 63\u2013101 (1989).","journal-title":"Free Radic. Biol. Med."},{"key":"964_CR24","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/jco.2005.23.16_suppl.3042","volume":"23","author":"GI Shapiro","year":"2005","unstructured":"Shapiro, G. I. et al. Phase I trial of ARQ 501, an activated checkpoint therapy (ACT) agent, in patients with advanced solid tumors. J. Clin. Oncol. 23, 3042\u20133042 (2005).","journal-title":"J. Clin. Oncol."},{"key":"964_CR25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41416-018-0278-4","volume":"119","author":"DE Gerber","year":"2018","unstructured":"Gerber, D. E. et al. Phase 1 study of ARQ 761, a \u03b2-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. Br. J. Cancer 119, 928\u2013936 (2018).","journal-title":"Br. J. Cancer"},{"key":"964_CR26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1039\/C7TX00223H","volume":"6","author":"TM Penning","year":"2017","unstructured":"Penning, T. M. Genotoxicity of ortho-quinones: reactive oxygen species versus covalent modification. Toxicol. Res. 6, 740\u2013754 (2017).","journal-title":"Toxicol. Res."},{"key":"964_CR27","doi-asserted-by":"publisher","first-page":"13369","DOI":"10.1073\/pnas.96.23.13369","volume":"96","author":"CJ Li","year":"1999","unstructured":"Li, C. J., Li, Y. Z., Pinto, A. V. & Pardee, A. B. Potent inhibition of tumor survival in vivo by \u03b2-lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc. Natl Acad. Sci. USA 96, 13369\u201313374 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"964_CR28","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ccell.2016.11.006","volume":"30","author":"X Huang","year":"2016","unstructured":"Huang, X. et al. Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly(ADP-ribose) polymerase nhibitors. Cancer Cell 30, 940\u2013952 (2016).","journal-title":"Cancer Cell"},{"key":"964_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1517\/13543784.2015.960077","volume":"24","author":"DW Sborov","year":"2015","unstructured":"Sborov, D. W., Haverkos, B. M. & Harris, P. J. Investigational cancer drugs targeting cell metabolism in clinical development. Expert Opin. Investig. Drugs 24, 79\u201394 (2015).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"964_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrd3137","volume":"9","author":"S Fulda","year":"2010","unstructured":"Fulda, S., Galluzzi, L. & Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 9, 447\u2013464 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"964_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","volume":"41","author":"Q Cui","year":"2018","unstructured":"Cui, Q. et al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist. Updat. 41, 1\u201325 (2018).","journal-title":"Drug Resist. Updat."},{"key":"964_CR32","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1038\/s41467-019-11238-1","volume":"10","author":"X Li","year":"2019","unstructured":"Li, X. et al. NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nature Commun. 10, 3251 (2019).","journal-title":"Nature Commun."},{"key":"964_CR33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jconrel.2014.12.027","volume":"200","author":"X Ma","year":"2015","unstructured":"Ma, X. et al. Esterase-activatable \u03b2-lapachone prodrug micelles for NQO1-targeted lung cancer therapy. J. Control. Release 200, 201\u2013211 (2015).","journal-title":"J. Control. Release"},{"key":"964_CR34","doi-asserted-by":"publisher","first-page":"7429","DOI":"10.1039\/C6TB02049F","volume":"4","author":"Y Zhou","year":"2016","unstructured":"Zhou, Y. et al. Lysosome-oriented, dual-stage pH-responsive polymeric micelles for \u03b2-lapachone delivery. J. Mater. Chem. B 4, 7429\u20137440 (2016).","journal-title":"J. Mater. Chem. B"},{"key":"964_CR35","unstructured":"Gao, J., Boothman, D., Zhou, Y. & Bey, E. PH-sensitive compositions for delivery of beta lapachone and methods of use. US patent 9,631,041 B2 (2017)."},{"key":"964_CR36","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1039\/C0PY00324G","volume":"2","author":"CA Blencowe","year":"2011","unstructured":"Blencowe, C. A., Russell, A. T., Greco, F., Hayes, W. & Thornthwaite, D. W. Self-immolative linkers in polymeric delivery systems. Polym. Chem. 2, 773\u2013790 (2011).","journal-title":"Polym. Chem."},{"key":"964_CR37","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-17-2391","volume":"77","author":"NG Caculitan","year":"2017","unstructured":"Caculitan, N. G. et al. Cathepsin B is dispensable for cellular processing of cathepsin B-cleavable antibody\u2013drug conjugates. Cancer Res. 77, 7027\u20137037 (2017).","journal-title":"Cancer Res."},{"key":"964_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1021\/acs.bioconjchem.7b00576","volume":"29","author":"D Zhang","year":"2018","unstructured":"Zhang, D. et al. Immolation of p-aminobenzyl ether linker and payload potency and stability determine the cell-killing activity of antibody\u2013drug conjugates with phenol-containing payloads. Bioconjugate Chem. 29, 267\u2013274 (2018).","journal-title":"Bioconjugate Chem."},{"key":"964_CR39","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.tet.2007.11.050","volume":"64","author":"MP Shurygina","year":"2008","unstructured":"Shurygina, M. P., Kurskii, Y. A., Chesnokov, S. A. & Abakumov, G. A. Products of photoreduction of 9,10-phenanthrenequinone in the presence of N,N-dimethylanilines and polymethylbenzenes. Tetrahedron 64, 1459\u20131466 (2008).","journal-title":"Tetrahedron"},{"key":"964_CR40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1134\/S0018143910030148","volume":"44","author":"MP Shurygina","year":"2010","unstructured":"Shurygina, M. P., Kurskii, Y. A., Druzhkov, N. O., Chesnokov, S. A. & Abakumov, G. A. Products and mechanisms of photochemical transformations of o-quinones. High Energy Chem. 44, 234\u2013238 (2010).","journal-title":"High Energy Chem."},{"key":"964_CR41","unstructured":"March, J. Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 3rd edn (Wiley, 1985)."},{"key":"964_CR42","unstructured":"Brown, H. C., McDaniel, D. H. & H\u00e4fliger, O. in Determination of Organic Structures by Physical Methods Vol 4. (eds Nachod, F. C. & Zuckerman, J. J.) (Academic Press, 1971)."},{"key":"964_CR43","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","volume":"21","author":"JC Shelley","year":"2007","unstructured":"Shelley, J. C. et al. Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des. 21, 681\u2013691 (2007).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"964_CR44","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10822-010-9349-1","volume":"24","author":"JR Greenwood","year":"2010","unstructured":"Greenwood, J. R., Calkins, D., Sullivan, A. P. & Shelley, J. C. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J. Comput. Aided Mol. Des. 24, 591\u2013604 (2010).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"964_CR45","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1021\/bc8001997","volume":"19","author":"JA Richard","year":"2008","unstructured":"Richard, J. A. et al. Latent fluorophores based on a self-immolative linker strategy and suitable for protease sensing. Bioconjugate Chem. 19, 1707\u20131718 (2008).","journal-title":"Bioconjugate Chem."},{"key":"964_CR46","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1002\/chem.200700142","volume":"13","author":"M Shamis","year":"2007","unstructured":"Shamis, M. & Shabat, D. Single-triggered AB6 self-immolative dendritic amplifiers. Chem. Eur. J. 13, 4523\u20134528 (2007).","journal-title":"Chem. Eur. J."},{"key":"964_CR47","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0891-5849(97)00337-7","volume":"24","author":"YP Chau","year":"1998","unstructured":"Chau, Y. P., Shiah, S. G., Don, M. J. & Kuo, M. L. Involvement of hydrogen peroxide in topoisomerase inhibitor beta-lapachone-induced apoptosis and differentiation in human leukemia cells. Free Radic. Biol. Med. 24, 660\u2013670 (1998).","journal-title":"Free Radic. Biol. Med."},{"key":"964_CR48","doi-asserted-by":"publisher","first-page":"6899","DOI":"10.1039\/C8SC02634C","volume":"9","author":"T Rodrigues","year":"2018","unstructured":"Rodrigues, T. et al. Machine intelligence decrypts \u03b2-lapachone as an allosteric 5-lipoxygenase inhibitor. Chem. Sci. 9, 6899\u20136903 (2018).","journal-title":"Chem. Sci."},{"key":"964_CR49","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1021\/bc025536j","volume":"13","author":"GM Dubowchik","year":"2002","unstructured":"Dubowchik, G. M. et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjugate Chem. 13, 855\u2013869 (2002).","journal-title":"Bioconjugate Chem."},{"key":"964_CR50","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1083\/jcb.90.3.665","volume":"90","author":"B Poole","year":"1981","unstructured":"Poole, B. & Ohkuma, S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J. Cell Biol. 90, 665\u2013669 (1981).","journal-title":"J. Cell Biol."},{"key":"964_CR51","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1248\/bpb1978.9.672","volume":"9","author":"M Tamai","year":"1986","unstructured":"Tamai, M. et al. In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64. J. Pharmacobiodyn. 9, 672\u2013677 (1986).","journal-title":"J. Pharmacobiodyn."},{"key":"964_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ar.22612","volume":"296","author":"C Yu","year":"2013","unstructured":"Yu, C. et al. Lysosome dysfunction enhances oxidative stress-induced apoptosis through ubiquitinated protein accumulation in HeLa cells. Anat. Rec. 296, 31\u201339 (2013).","journal-title":"Anat. Rec."},{"key":"964_CR53","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1111\/febs.15227","volume":"287","author":"M Poreba","year":"2020","unstructured":"Poreba, M. Protease-activated prodrugs: strategies, challenges, and future directions. FEBS J. 287, 1936\u20131969 (2020).","journal-title":"FEBS J."},{"key":"964_CR54","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/prca.201300105","volume":"8","author":"N Aggarwal","year":"2014","unstructured":"Aggarwal, N. & Sloane, B. F. Cathepsin B: multiple roles in cancer. Proteomics Clin. Appl. 8, 427\u2013437 (2014).","journal-title":"Proteomics Clin. Appl."},{"key":"964_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrc2981","volume":"11","author":"RA Cairns","year":"2011","unstructured":"Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85\u201395 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"964_CR56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.leukres.2016.05.025","volume":"47","author":"J Kell","year":"2016","unstructured":"Kell, J. Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia. Leuk. Res. 47, 149\u2013160 (2016).","journal-title":"Leuk. Res."},{"key":"964_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/jcm5030033","volume":"5","author":"JN Saultz","year":"2016","unstructured":"Saultz, J. N. & Garzon, R. Acute myeloid leukemia: a concise review. J. Clin. Med. 5, 33 (2016).","journal-title":"J. Clin. Med."},{"key":"964_CR58","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie, D., Helgason, G. V. & Copland, M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat. Rev. Cancer 20, 158\u2013173 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"964_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13046-018-0797-0","volume":"37","author":"R Prieto-Bermejo","year":"2018","unstructured":"Prieto-Bermejo, R., Romo-Gonz\u00e1lez, M., P\u00e9rez-Fern\u00e1ndez, A., Ijurko, C. & Hern\u00e1ndez-Hern\u00e1ndez, \u00c1. Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side. J. Exp. Clin. Cancer Res. 37, 125 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"964_CR60","first-page":"3893","volume":"62","author":"WH Miller Jr.","year":"2002","unstructured":"Miller, W. H. Jr., Schipper, H. M., Lee, J. S., Singer, J. & Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res. 62, 3893\u20133903 (2002).","journal-title":"Cancer Res."},{"key":"964_CR61","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4172\/2157-7609.1000186","volume":"6","author":"BK Sinha","year":"2015","unstructured":"Sinha, B. K. & Mason, R. P. Is metabolic activation of topoisomerase II poisons important in the mechanism of cytotoxicity? J. Drug Metab. Toxicol. 6, 186 (2015).","journal-title":"J. Drug Metab. Toxicol."},{"key":"964_CR62","doi-asserted-by":"publisher","first-page":"5244","DOI":"10.1158\/0008-5472.CAN-13-3012","volume":"74","author":"J Roos","year":"2014","unstructured":"Roos, J. et al. 5-Lipoxygenase Is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia. Cancer Res. 74, 5244\u20135255 (2014).","journal-title":"Cancer Res."},{"key":"964_CR63","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/ng.389","volume":"41","author":"Y Chen","year":"2009","unstructured":"Chen, Y., Hu, Y., Zhang, H., Peng, C. & Li, S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 41, 783\u2013792 (2009).","journal-title":"Nat. Genet."},{"key":"964_CR64","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-17-1077","volume":"17","author":"Y Kovtun","year":"2018","unstructured":"Kovtun, Y. et al. IMGN779, a novel CD33-targeting antibody\u2013drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML. Mol. Cancer Ther. 17, 1271\u20131279 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"964_CR65","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.2289","volume":"30","author":"PD Senter","year":"2012","unstructured":"Senter, P. D. & Sievers, E. L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30, 631\u2013637 (2012).","journal-title":"Nat. Biotechnol."},{"key":"964_CR66","doi-asserted-by":"publisher","first-page":"13128","DOI":"10.1038\/ncomms13128","volume":"7","author":"B Bernardim","year":"2016","unstructured":"Bernardim, B. et al. Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents. Nat. Commun. 7, 13128\u201313128 (2016).","journal-title":"Nat. Commun."},{"key":"964_CR67","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41596-018-0083-9","volume":"14","author":"B Bernardim","year":"2019","unstructured":"Bernardim, B. et al. Efficient and irreversible antibody\u2013cysteine bioconjugation using carbonylacrylic reagents. Nat. Protoc. 14, 86\u201399 (2019).","journal-title":"Nat. Protoc."},{"key":"964_CR68","doi-asserted-by":"publisher","first-page":"8208","DOI":"10.1002\/chem.201900441","volume":"25","author":"HG Lerchen","year":"2019","unstructured":"Lerchen, H. G. et al. Antibody\u2013prodrug conjugates with KSP inhibitors and legumain-mediated metabolite formation. Chem. Eur. J. 25, 8208\u20138213 (2019).","journal-title":"Chem. Eur. J."},{"key":"964_CR69","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon, R. P. et al. Reducing hydrophobicity of homogeneous antibody\u2013drug conjugates improves pharmacokinetics and therapeutic index. Nat. Biotechnol. 33, 733\u2013735 (2015).","journal-title":"Nat. Biotechnol."},{"key":"964_CR70","doi-asserted-by":"publisher","unstructured":"Pyzik, M. et al. The neonatal Fc receptor (FcRn): a misnomer? Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.01540 (2019).","DOI":"10.3389\/fimmu.2019.01540"},{"key":"964_CR71","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.2147\/DDDT.S135571","volume":"11","author":"M Kalim","year":"2017","unstructured":"Kalim, M. et al. Intracellular trafficking of new anticancer therapeutics: antibody\u2013drug conjugates. Drug Des. Devel. Ther. 11, 2265\u20132276 (2017).","journal-title":"Drug Des. Devel. Ther."},{"key":"964_CR72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","volume":"5","author":"M Ritchie","year":"2013","unstructured":"Ritchie, M., Tchistiakova, L. & Scott, N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. mAbs 5, 13\u201321 (2013).","journal-title":"mAbs"},{"key":"964_CR73","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","volume":"130","author":"FR Appelbaum","year":"2017","unstructured":"Appelbaum, F. R. & Bernstein, I. D. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood 130, 2373\u20132376 (2017).","journal-title":"Blood"},{"key":"964_CR74","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","volume":"127","author":"EM Stein","year":"2016","unstructured":"Stein, E. M. & Tallman, M. S. Emerging therapeutic drugs for AML. Blood 127, 71\u201378 (2016).","journal-title":"Blood"},{"key":"964_CR75","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.1039\/C7SC05266A","volume":"9","author":"E Cini","year":"2018","unstructured":"Cini, E. et al. Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation. Chem. Sci. 9, 6490\u20136496 (2018).","journal-title":"Chem. Sci."},{"key":"964_CR76","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1177\/0192623318803059","volume":"46","author":"L Mecklenburg","year":"2018","unstructured":"Mecklenburg, L. A brief introduction to antibody\u2013drug conjugates for toxicologic pathologists. Toxicol. Pathol. 46, 746\u2013752 (2018).","journal-title":"Toxicol. Pathol."},{"key":"964_CR77","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ejmech.2019.06.056","volume":"179","author":"EN da Silva J\u00fanior","year":"2019","unstructured":"da Silva J\u00fanior, E. N. et al. Synthesis of quinones with highlighted biological applications: a critical update on the strategies towards bioactive compounds with emphasis on lapachones. Eur. J. Med. Chem. 179, 863\u2013915 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"964_CR78","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1089\/adt.2008.151","volume":"6","author":"PA Johnston","year":"2008","unstructured":"Johnston, P. A. et al. Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev. Technol. 6, 505\u2013518 (2008).","journal-title":"Assay Drug Dev. Technol."},{"key":"964_CR79","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1096\/fj.02-0815fje","volume":"17","author":"L Fischer","year":"2003","unstructured":"Fischer, L., Szellas, D., R\u00e5dmark, O., Steinhilber, D. & Werz, O. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J. 17, 949\u2013951 (2003).","journal-title":"FASEB J."},{"key":"964_CR80","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0378-4347(00)82742-5","volume":"493","author":"D Steinhilber","year":"1989","unstructured":"Steinhilber, D., Herrmann, T. & Roth, H. J. Separation of lipoxins and leukotrienes from human granulocytes by high-performance liquid chromatography with a Radial-Pak cartridge after extraction with an octadecyl reversed-phase column. J. Chromatogr. 493, 361\u2013366 (1989).","journal-title":"J. Chromatogr."},{"key":"964_CR81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/19420862.2018.1548233","volume":"11","author":"X Lu","year":"2019","unstructured":"Lu, X. et al. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. MAbs 11, 45\u201357 (2019).","journal-title":"MAbs"},{"key":"964_CR82","unstructured":"Queen, C. L. & Selick, H. E. Humanized immunoglobulins. US patent US5585089A (1996)."},{"key":"964_CR83","unstructured":"Hamann, P. R. et al. Conjugates of methyltrithio antitumor agents and intermediates for their synthesis. US patent US5773001A (1998)."},{"key":"964_CR84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/btpr.1809","volume":"30","author":"O Daramola","year":"2014","unstructured":"Daramola, O. et al. A high-yielding CHO transient system: Coexpression of genes encoding EBNA-1 and GS enhances transient protein expression. Biotechnol. Progress 30, 132\u2013141 (2014).","journal-title":"Biotechnol. Progress"},{"key":"964_CR85","doi-asserted-by":"publisher","first-page":"113466","DOI":"10.1016\/j.jpba.2020.113466","volume":"188","author":"WC Putnam","year":"2020","unstructured":"Putnam, W. C., Kallem, R. R., Subramaniyan, I., Beg, M. S. & Edpuganti, V. Bioanalytical method development and validation of a liquid chromatography\u2013tandem mass spectrometry method for determination of \u03b2-lapachone in human plasma. J. Pharm. Biomed. Anal. 188, 113466 (2020).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"964_CR86","unstructured":"M. J. Frisch, et al. Gaussian 16 Rev. C.01. (Gaussian, 2016)."},{"key":"964_CR87","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00214-007-0310-x","volume":"120","author":"Y Zhao","year":"2008","unstructured":"Zhao, Y. & Truhlar, D. G. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals. Theor. Chem. Account 120, 215\u2013241 (2008).","journal-title":"Theor. Chem. Account"},{"key":"964_CR88","doi-asserted-by":"publisher","first-page":"114110","DOI":"10.1063\/1.3359469","volume":"132","author":"G Scalmani","year":"2010","unstructured":"Scalmani, G. & Frisch, M. J. Continuous surface charge polarizable continuum models of solvation. I. General formalism. J. Chem. Phys. 132, 114110 (2010).","journal-title":"J. Chem. Phys."},{"key":"964_CR89","doi-asserted-by":"publisher","first-page":"14556","DOI":"10.1021\/jp205508z","volume":"115","author":"RF Ribeiro","year":"2011","unstructured":"Ribeiro, R. F., Marenich, A. V., Cramer, C. J. & Truhlar, D. G. Use of solution-phase vibrational frequencies in continuum models for the free energy of solvation. J. Phys. Chem. B 115, 14556\u201314562 (2011).","journal-title":"J. Phys. Chem. B"},{"key":"964_CR90","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1063\/1.456010","volume":"90","author":"C Gonzalez","year":"1989","unstructured":"Gonzalez, C. & Schlegel, H. B. An improved algorithm for reaction path following. J. Chem. Phys. 90, 2154\u20132161 (1989).","journal-title":"J. Chem. Phys."},{"key":"964_CR91","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.1021\/j100377a021","volume":"94","author":"C Gonzalez","year":"1990","unstructured":"Gonzalez, C. & Schlegel, H. B. Reaction path following in mass-weighted internal coordinates. J. Phys. Chem. 94, 5523\u20135527 (1990).","journal-title":"J. Phys. Chem."},{"key":"964_CR92","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.1039\/b810189b","volume":"10","author":"J-D Chai","year":"2008","unstructured":"Chai, J.-D. & Head-Gordon, M. Long-range corrected hybrid density functionals with damped atom\u2013atom dispersion corrections. Phys. Chem. Chem. Phys. 10, 6615\u20136620 (2008).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"964_CR93","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1021\/jp810292n","volume":"113","author":"AV Marenich","year":"2009","unstructured":"Marenich, A. V., Cramer, C. J. & Truhlar, D. G. Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. J. Phys. Chem. B 113, 6378\u20136396 (2009).","journal-title":"J. Phys. Chem. B"}],"container-title":["Nature Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41557-022-00964-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41557-022-00964-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41557-022-00964-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T01:06:24Z","timestamp":1666573584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41557-022-00964-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":93,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1038\/s41557-022-00964-7","relation":{},"ISSN":["1755-4330","1755-4349"],"issn-type":[{"value":"1755-4330","type":"print"},{"value":"1755-4349","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.R., V.Z., E.S. and E.M. are or were formerly employed by AstraZeneca plc. L.D., J.B., E.G.d.M. and G.J.L.B. are inventors on a patent application (GB2207691.3) that incorporates discoveries described in this manuscript. T.R. and G.J.L.B. are inventors on a patent that describes the discovery of the allosteric inhibition of 5-LO by \u03b2-lapachone (PCT\/PT2018\/050029), which is related to parts of the work related in this manuscript. The authors of this article declare that V. Cantrill, who was involved with the editing of this article, is employed by G.J.L.B. as a research coordinator at the University of Cambridge. V. Cantrill is married to S. Cantrill, who is the Chief Editor of <i>Nature Chemistry<\/i>. All other authors declare no competing interests.<b>Publisher Note:<\/b> The editorial team of <i>Nature Chemistry<\/i> declare that Stuart Cantrill has had no involvement in the editorial handling of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}